UBS/CALL/ROCHE GS/600.004/0.025/24.12.25 Stock

Warrant

EROG8U

CH1179515015

Real-time Bid/Ask 08:30:13 2024-06-17 EDT
0.012 CHF / 0.031 CHF +10.00% Intraday chart for UBS/CALL/ROCHE GS/600.004/0.025/24.12.25

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
EROG8U
ISINCH1179515015
Date issued 2022-04-10
Strike 600 CHF
Maturity 2025-12-24 (555 Days)
Parity 40 : 1
Emission price 0.17 CHF
Emission volume N/A
Settlement physical
Currency CHF

Technical Indicators

Highest since issue 0.15 CHF
Lowest since issue 0.015 CHF
Spread 0.019 CHF
Spread %61.29%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus
  1. Stock Market
  2. Warrants
  3. EROG8U Warrant